49. 全身性エリテマトーデス [臨床試験数:827,薬物数:638(DrugBank:168),標的遺伝子数:108,標的パスウェイ数:191

Searched query = "Systemic lupus erythematosus", "SLE"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
7 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2010-023396-25-PL30/05/201223/09/2011A study to assess the safety and effectiveness of SL101 in the treatment of systemic lupus erythematosus (SLE)Phase IIa, 2:2:1 randomised, double-blind, placebo-controlled, parallel group, multi-centre clinical trial to investigate the safety, efficacy and pharmacokinetics of recombinant human soluble Fc-gamma receptor IIb (SM101) for intravenous application in the treatment of systemic lupus erythematosus (SLE) patients with or without a history of lupus nephritis - SMILE Systemic lupus erythematosus (SLE)
MedDRA version: 15.1Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Body processes [G] - Immune system processes [G12]
Product Name: soluble Fc-gamma receptor IIb
Product Code: SM101
INN or Proposed INN: .
Other descriptive name: soluble Fc receptor
SuppreMol GmbHNULLNot RecruitingFemale: yes
Male: yes
50Phase 2France;Czech Republic;Belgium;Spain;Poland;Australia;Netherlands;Germany;Italy;United Kingdom
2EUCTR2010-023396-25-NL16/02/201224/10/2011A study to assess the safety and effectiveness of SL101 in the treatment of systemic lupus erythematosus (SLE)Phase IIa, 2:2:1 randomised, double-blind, placebo-controlled, parallel group, multi-centre clinical trial to investigate the safety, efficacy and pharmacokinetics of recombinant human soluble Fc-gamma receptor IIb (SM101) for intravenous application in the treatment of systemic lupus erythematosus (SLE) patients with or without a history of lupus nephritis - SMILE Systemic lupus erythematosus (SLE)
MedDRA version: 14.1Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Body processes [G] - Immune system processes [G12]
Product Name: soluble Fc-gamma receptor IIb
Product Code: SM101
INN or Proposed INN: .
Other descriptive name: soluble Fc receptor
SuppreMol GmbHNULLNot RecruitingFemale: yes
Male: yes
50Phase 2France;Czech Republic;Belgium;Spain;Poland;Australia;Germany;Netherlands;Italy;United Kingdom
3EUCTR2010-023396-25-DE09/11/201114/06/2011A study to assess the safety and effectiveness of SL101 in the treatment of systemic lupus erythematosus (SLE)Phase IIa, 2:2:1 randomised, double-blind, placebo-controlled,parallel group, multi-centre clinical trial toinvestigate the safety, efficacy and pharmacokinetics ofrecombinant human soluble Fc-gamma receptor IIb(SM101) for intravenous application in the treatment ofsystemic lupus erythematosus (SLE) patients with orwithout a history of lupus nephritis - SMILE Systemic lupus erythematosus (SLE)
MedDRA version: 14.1Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Body processes [G] - Immune system processes [G12]
Product Name: soluble Fc-gamma receptor IIb
Product Code: SM101
INN or Proposed INN: .
Other descriptive name: soluble Fc receptor
SuppreMol GmbHNULLNot RecruitingFemale: yes
Male: yes
50Phase 2France;Czech Republic;Belgium;Spain;Poland;Australia;Netherlands;Germany;Italy;United Kingdom
4EUCTR2010-023396-25-CZ13/10/201101/08/2011A study to assess the safety and effectiveness of SL101 in the treatment of systemic lupus erythematosus (SLE)Phase IIa, 2:2:1 randomised, double-blind, placebo-controlled,parallel group, multi-centre clinical trial toinvestigate the safety, efficacy and pharmacokinetics ofrecombinant human soluble Fc-gamma receptor IIb(SM101) for intravenous application in the treatment ofsystemic lupus erythematosus (SLE) patients with orwithout a history of lupus nephritis - SMILE Systemic lupus erythematosus (SLE)
MedDRA version: 14.1Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Body processes [G] - Immune system processes [G12]
Product Name: soluble Fc-gamma receptor IIb
Product Code: SM101
INN or Proposed INN: .
Other descriptive name: soluble Fc receptor
SuppreMol GmbHNULLNot RecruitingFemale: yes
Male: yes
50Phase 2France;Czech Republic;Belgium;Spain;Poland;Australia;Netherlands;Germany;Italy;United Kingdom
5EUCTR2010-023396-25-GB22/09/201111/04/2011A study to assess the safety and effectiveness of SL101 in the treatment of systemic lupus erythematosus (SLE)Phase IIa, 2:2:1 randomised, double-blind, placebo-controlled,parallel group, multi-centre clinical trial toinvestigate the safety, efficacy and pharmacokinetics ofrecombinant human soluble Fc-gamma receptor IIb(SM101) for intravenous application in the treatment ofsystemic lupus erythematosus (SLE) patients with orwithout a history of lupus nephritis - SMILE Systemic lupus erythematosus (SLE)
MedDRA version: 14.1Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Body processes [G] - Immune system processes [G12]
Product Name: soluble Fc-gamma receptor IIb
Product Code: SM101
INN or Proposed INN: .
Other descriptive name: soluble Fc receptor
SuppreMol GmbHNULLNot RecruitingFemale: yes
Male: yes
50Phase 2France;Czech Republic;Belgium;Spain;Poland;Australia;Netherlands;Germany;Italy;United Kingdom
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2010-023396-25-ES20/09/201111/11/2011A study to assess the safety and effectiveness of SL101 in the treatment of systemic lupus erythematosus (SLE)Ensayo clínico multicéntrico, de grupos paralelos, controlado por placebo, doble ciego, randomizado 2:2:1, de fase IIa, para investigar la seguridad, eficacia y farmacocinética del receptor Fc-gamma IIb recombinante, humano, soluble (SM101) para su aplicación intravenosa en el tratamiento de pacientes con lupus eritematoso sistémico (LES) con o sin un historial de nefritis lúpica - SMILE lupus eritematoso sistémico (LES)
MedDRA version: 14.0Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Body processes [G] - Immune system processes [G12]
Product Name: soluble Fc-gamma receptor IIb
Product Code: SM101
Other descriptive name: soluble Fc receptor
SuppreMol GmbHNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
50Czech Republic;United Kingdom;Germany;Netherlands;Belgium;France;Spain;Italy;Poland;Australia
7EUCTR2010-023396-25-BE13/07/201120/04/2011A study to assess the safety and effectiveness of SL101 in the treatment of systemic lupus erythematosus (SLE)Phase IIa, 2:2:1 randomised, double-blind, placebo-controlled,parallel group, multi-centre clinical trial toinvestigate the safety, efficacy and pharmacokinetics ofrecombinant human soluble Fc-gamma receptor IIb(SM101) for intravenous application in the treatment ofsystemic lupus erythematosus (SLE) patients with orwithout a history of lupus nephritis - SMILE Systemic lupus erythematosus (SLE)
MedDRA version: 13.1Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Body processes [G] - Immune system processes [G12]
Product Name: soluble Fc-gamma receptor IIb
Product Code: SM101
Other descriptive name: soluble Fc receptor
SuppreMol GmbHNULLNot RecruitingFemale: yes
Male: yes
50Phase 2France;Czech Republic;Spain;Poland;Belgium;Australia;Netherlands;Germany;Italy;United Kingdom